{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T06:58:32Z","timestamp":1708757912307},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T00:00:00Z","timestamp":1278374400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Optimal management and outcome of primary gastric lymphoma (PGL) have not been well defined in the rituximab era. This study aimed to analyze the clinical characteristics, prognostic factors, and roles of different treatment modalities in Chinese patients with PGL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The clinicopathological features of 83 Chinese patients with PGL were retrospectively reviewed. Staging was performed according to the Lugano staging system for gastrointestinal non-Hodgkin's lymphoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The predominant pathologic subtype among Chinese patients with PGL in our study was diffuse large B cell lymphoma (DLBCL), followed by mucosa-associated lymphoid tissue (MALT) lymphoma. Among the 57 patients with gastric DLBCL, 20 patients (35.1%) were classified as the germinal center B cell-like (GCB) subtype and 37 patients (64.9%) as the non-GCB subtype. The 83 patients had a five-year overall survival (OS) and event-free survival (EFS) of 52% and 59%, respectively. Cox regression analysis showed that stage-modified international prognostic index (IPI) and performance status (PS) were independent predictors of survival. In the 67 B-cell lymphoma patients who received chemotherapy, 36 patients treated with rituximab (at least 3 cycles) had a mean OS of 72 months (95% CI 62-81) versus 62 months (95% CI 47-76) for patients without rituximab treatment (P = 0.021).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The proportion of Chinese gastric DLBCL cases with non-GCB subtype was higher than the GCB subtype. Stage-modified IPI and PS were effective prognostic factors in Chinese patients with PGL. Our data suggested that primary gastric B-cell lymphoma might have an improved outcome with rituximab in addition to chemotherapy. More studies are necessary, preferentially large prospective randomized clinical trials to obtain more information on the impact of the rituximab in the primary gastric B-cell lymphoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-10-358","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T06:13:47Z","timestamp":1278483227000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors"],"prefix":"10.1186","volume":"10","author":[{"given":"JiaJia","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WenQi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RuiHua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HuiQiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhongJun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoFei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhongZhen","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TongYu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhiMing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,6]]},"reference":[{"issue":"1","key":"2157_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.critrevonc.2007.01.003","volume":"63","author":"AJ Ferreri","year":"2007","unstructured":"Ferreri AJ, Montalban C: Primary diffuse large B-cell lymphoma of the stomach. Critical reviews in oncology\/hematology. 2007, 63 (1): 65-71. 10.1016\/j.critrevonc.2007.01.003.","journal-title":"Critical reviews in oncology\/hematology"},{"key":"2157_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/bjs.18004921319","volume":"49","author":"IM Dawson","year":"1961","unstructured":"Dawson IM, Cornes JS, Morson BC: Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. The British journal of surgery. 1961, 49: 80-89. 10.1002\/bjs.18004921319.","journal-title":"The British journal of surgery"},{"issue":"10","key":"2157_CR3","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1080\/10428190600709226","volume":"47","author":"G Papaxoinis","year":"2006","unstructured":"Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leukemia & lymphoma. 2006, 47 (10): 2140-2146.","journal-title":"Leukemia & lymphoma"},{"issue":"8","key":"2157_CR4","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1245\/s10434-006-9244-0","volume":"14","author":"H Medina-Franco","year":"2007","unstructured":"Medina-Franco H, Germes SS, Maldonado CL: Prognostic factors in primary gastric lymphoma. Annals of surgical oncology. 2007, 14 (8): 2239-2245. 10.1245\/s10434-006-9244-0.","journal-title":"Annals of surgical oncology"},{"issue":"8","key":"2157_CR5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1200\/JCO.1994.12.8.1673","volume":"12","author":"F d'Amore","year":"1994","unstructured":"d'Amore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS: Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol. 1994, 12 (8): 1673-1684.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2157_CR6","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1200\/JCO.2001.19.18.3861","volume":"19","author":"P Koch","year":"2001","unstructured":"Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, et al: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01\/92. J Clin Oncol. 2001, 19 (18): 3861-3873.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2157_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/hon.660","volume":"19","author":"JK Chan","year":"2001","unstructured":"Chan JK: The new World Health Organization classification of lymphomas: the past, the present and the future. Hematological oncology. 2001, 19 (4): 129-150. 10.1002\/hon.660.","journal-title":"Hematological oncology"},{"issue":"5","key":"2157_CR8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/oxfordjournals.annonc.a058869","volume":"5","author":"A Rohatiner","year":"1994","unstructured":"Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M, et al: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994, 5 (5): 397-400.","journal-title":"Ann Oncol"},{"issue":"6","key":"2157_CR9","first-page":"457","volume":"159","author":"L Santacroce","year":"2008","unstructured":"Santacroce L, Cagiano R, Del Prete R, Bottalico L, Sabatini R, Carlaio RG, Prejbeanu R, Vermesan H, Dragulescu SI, Vermesan D, et al: Helicobacter pylori infection and gastric MALTomas: an up-to-date and therapy highlight. La Clinica terapeutica. 2008, 159 (6): 457-462.","journal-title":"La Clinica terapeutica"},{"issue":"9","key":"2157_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00277-003-0677-2","volume":"82","author":"T Wundisch","year":"2003","unstructured":"Wundisch T, Kim TD, Thiede C, Morgner A, Alpen B, Stolte M, Neubauer A: Etiology and therapy of Helicobacter pylori-associated gastric lymphomas. Annals of hematology. 2003, 82 (9): 535-545. 10.1007\/s00277-003-0677-2.","journal-title":"Annals of hematology"},{"issue":"12","key":"2157_CR11","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdn525","volume":"19","author":"A Psyrri","year":"2008","unstructured":"Psyrri A, Papageorgiou S, Economopoulos T: Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008, 19 (12): 1992-1999. 10.1093\/annonc\/mdn525.","journal-title":"Ann Oncol"},{"issue":"2","key":"2157_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/1097-0142(197808)42:2<693::AID-CNCR2820420241>3.0.CO;2-J","volume":"42","author":"KJ Lewin","year":"1978","unstructured":"Lewin KJ, Ranchod M, Dorfman RF: Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer. 1978, 42 (2): 693-707. 10.1002\/1097-0142(197808)42:2<693::AID-CNCR2820420241>3.0.CO;2-J.","journal-title":"Cancer"},{"issue":"1","key":"2157_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004, 103 (1): 275-282. 10.1182\/blood-2003-05-1545.","journal-title":"Blood"},{"issue":"12","key":"2157_CR14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1023\/A:1008351427601","volume":"10","author":"S Cortelazzo","year":"1999","unstructured":"Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pasini F, Pinotti G, Bertini M, et al: Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 1999, 10 (12): 1433-1440. 10.1023\/A:1008351427601.","journal-title":"Ann Oncol"},{"issue":"4","key":"2157_CR15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999, 17 (4): 1244-","journal-title":"J Clin Oncol"},{"issue":"4","key":"2157_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2141.2006.06444.x","volume":"136","author":"PF Ferrucci","year":"2007","unstructured":"Ferrucci PF, Zucca E: Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?. British journal of haematology. 2007, 136 (4): 521-538. 10.1111\/j.1365-2141.2006.06444.x.","journal-title":"British journal of haematology"},{"issue":"7","key":"2157_CR17","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2006-05-022517","volume":"108","author":"YW Chen","year":"2006","unstructured":"Chen YW, Hu XT, Liang AC, Au WY, So CC, Wong ML, Shen L, Tao Q, Chu KM, Kwong YL, et al: High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood. 2006, 108 (7): 2373-2383. 10.1182\/blood-2006-05-022517.","journal-title":"Blood"},{"issue":"10","key":"2157_CR18","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-07-4946","volume":"14","author":"S Nakamura","year":"2008","unstructured":"Nakamura S, Ye H, Bacon CM, Goatly A, Liu H, Kerr L, Banham AH, Streubel B, Yao T, Tsuneyoshi M, et al: Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. Clin Cancer Res. 2008, 14 (10): 3002-3010. 10.1158\/1078-0432.CCR-07-4946.","journal-title":"Clin Cancer Res"},{"issue":"8871","key":"2157_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/0140-6736(93)91408-E","volume":"342","author":"T Hussell","year":"1993","unstructured":"Hussell T, Isaacson PG, Crabtree JE, Spencer J: The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet. 1993, 342 (8871): 571-574. 10.1016\/0140-6736(93)91408-E.","journal-title":"Lancet"},{"issue":"5","key":"2157_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00277-008-0604-7","volume":"88","author":"MK Ang","year":"2009","unstructured":"Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST: Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Annals of hematology. 2009, 88 (5): 417-424. 10.1007\/s00277-008-0604-7.","journal-title":"Annals of hematology"},{"issue":"12","key":"2157_CR21","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2439::AID-CNCR19>3.0.CO;2-Q","volume":"82","author":"TS Mok","year":"1998","unstructured":"Mok TS, Steinberg J, Chan AT, Yeo WM, Hui P, Leung TW, Johnson P: Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. Cancer. 1998, 82 (12): 2439-2448. 10.1002\/(SICI)1097-0142(19980615)82:12<2439::AID-CNCR19>3.0.CO;2-Q.","journal-title":"Cancer"},{"issue":"28","key":"2157_CR22","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1200\/JCO.2005.04.031","volume":"23","author":"P Koch","year":"2005","unstructured":"Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, et al: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02\/96). J Clin Oncol. 2005, 23 (28): 7050-7059. 10.1200\/JCO.2005.04.031.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2157_CR23","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2001.19.18.3874","volume":"19","author":"P Koch","year":"2001","unstructured":"Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, et al: Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01\/92. J Clin Oncol. 2001, 19 (18): 3874-3883.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2157_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00403-009-0967-1","volume":"301","author":"N Colovic","year":"2009","unstructured":"Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M: Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Archives of dermatological research. 2009, 301 (9): 689-692. 10.1007\/s00403-009-0967-1.","journal-title":"Archives of dermatological research"},{"issue":"2","key":"2157_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14712590802650581","volume":"9","author":"M Migkou","year":"2009","unstructured":"Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E: Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert opinion on biological therapy. 2009, 9 (2): 207-220. 10.1517\/14712590802650581.","journal-title":"Expert opinion on biological therapy"},{"issue":"9","key":"2157_CR26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","volume":"13","author":"X Zhou","year":"2008","unstructured":"Zhou X, Hu W, Qin X: The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. The oncologist. 2008, 13 (9): 954-966. 10.1634\/theoncologist.2008-0089.","journal-title":"The oncologist"},{"issue":"7","key":"2157_CR27","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/annonc\/mdh261","volume":"15","author":"S Wohrer","year":"2004","unstructured":"Wohrer S, Puspok A, Drach J, Hejna M, Chott A, Raderer M: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol. 2004, 15 (7): 1086-1090. 10.1093\/annonc\/mdh261.","journal-title":"Ann Oncol"},{"issue":"6","key":"2157_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1600-0609.2010.01426.x","volume":"84","author":"D Chihara","year":"2010","unstructured":"Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima Y: Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. European journal of haematology. 2010, 84 (6): 493-498. 10.1111\/j.1600-0609.2010.01426.x.","journal-title":"European journal of haematology"},{"issue":"1","key":"2157_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/cbr.2008.0507","volume":"24","author":"A Aviles","year":"2009","unstructured":"Aviles A, Castaneda C, Cleto S, Neri N, Huerta-Guzman J, Gonzalez M, Nambo MJ: Rituximab and chemotherapy in primary gastric lymphoma. Cancer biotherapy & radiopharmaceuticals. 2009, 24 (1): 25-28.","journal-title":"Cancer biotherapy & radiopharmaceuticals"},{"issue":"9","key":"2157_CR30","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","volume":"23","author":"G Martinelli","year":"2005","unstructured":"Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, et al: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005, 23 (9): 1979-1983. 10.1200\/JCO.2005.08.128.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-358\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:18:02Z","timestamp":1630613882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["2157"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-358","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,6]]},"assertion":[{"value":"4 December 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"358"}}